Pfizer Inks Global License to Genomatix Software and Databases
Complete the form below to unlock access to ALL audio articles.
Genomatix Software, Inc. the US branch of Munich (Germany) based Genomatix Software GmbH, announced that it has reached an agreement with Pfizer Pharmaceuticals to provide Genomatix software and data content to Pfizer sites across the globe.
The Genomatix tools licensed by Pfizer are designed to show how genes are regulated at a molecular level, and Pfizer scientists will use the software and data content to help understand the molecular basis of how their potential drug targets may be co-regulated with other important targets, producing potential desirable or unwanted side-effects.
“Adding Genomatix to Pfizer´s existing genomics software capabilities was a natural choice.” said Peter Grant, CEO of Genomatix Software, Inc.
“Our broad set of capabilities are a good compliment to those that Pfizer already has in house. We are pleased to be a part of Pfizer’s significant effort in molecular genomics. We believe our tools will provide a great value to their research effort, but the proof is always in the results. Now the fun really begins!” he concluded.
